PLAUR and kidney disorder: Limitations of the current study include the selection of different cohorts of patients with different underlying diseases (“focal sclerosis” or “chronic glomerulonephritis” in cohort 1 versus various kidney diseases in cohort 2), different timing of serum sample collection (pre-transplant in cohort 1 versus 1 year post-transplant in cohort 2), and the use of different assays for suPAR measurements (uPAR Quantikine® ELISA kit in cohort 1 versus suPARnostic kit in cohort 2).